ScreenerHero

RZLTRezolute, Inc.

NAS · US · Healthcare · Biotechnology · rezolutebio.com
5.090USD+7.84%Mkt Cap: 490.13M $P/E: —

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously ad…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap490.13M $
Enterprise Value329.57M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-74.41M $
Revenue/Share—
Last Price5.090 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.44
PEG—
EV/EBITDA-3.84
EV/Revenue—
P/S—
P/B4.17
EPS (TTM)-0.80
EPS (Forward)-0.63
52W Range
1.07039% of range11.46
52W High11.46 USD
52W Low1.070 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.90%
ROA-42.40%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-69.08M $
CapEx (TTM)—
FCF Margin—
FCF Yield-8.92%
Net Debt-119.16M $
Net Debt/EBITDA1.39
Balance Sheet
Debt/Equity0.01
Current Ratio15.84
Quick Ratio15.61
Book Value/Sh1.118 USD
Cash/Share1.249 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 13, 2020
Splits
Last Split1:50
Split DateOct 13, 2020
Analyst Consensus
Rating—
Target (Mean)7.667 USD
Upside (mean)+50.6%
Target Range4.000 USD – 14.00 USD
$4.000+50.6% to mean$14.00
# Analysts9
Ownership
Shares Out.96.29M
Float60.49M
Insiders10.15%
Institutions98.38%
Short Interest
Short Ratio10.8d
Short % Float26.39%
Short % Out.17.53%
Shares Short16.88M
Short (prev mo.)16.41M
Technical
SMA 504.772 (+6.7%)
SMA 2004.401 (+15.7%)
Beta0.62
S&P 52W Chg18.16%
Avg Vol (30d)1.38M
Avg Vol (10d)987.28K
Technical Indicators
RSI (14)59.9
MACD0.0138
MACD Signal0.0088
MACD Hist.+0.0050
BB Upper5.181 USD
BB Middle4.805 USD
BB Lower4.429 USD
BB Width15.65%
ATR (14)0.3364 USD
Vol Ratio (20d)5.96x